The following invention relates to collagen hydrolysate for use as an active substance in the treatment and/or prophylaxis of periodontitis or gingivitis.

The following invention relates to collagen hydrolysate for use as an active substance in the treatment and/or prophylaxis of periodontitis or gingivitis.

The invention is directed to a food product for use in the prevention, inhibition or treatment of tooth decay and other dental conditions, diseases and disorders, wherein said food product is a chewing gum comprising at least one cannabinoid.

The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (IL)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of NF-κB and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)-RANK signaling pathway, and suppresses the expression of a RANKL or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (TRAP), cathepsin K, or TNF receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration. Moreover, the peptide of the present invention can contribute to osteoblast differentiation by promoting the expression of osteoblast differentiation markers such as osteocalcin (OCN), osteoprotegerin (OPG), bone sialoprotein (BSP), or osteopontin (OPN). Therefore, the superior activity and stability of the peptide of the present invention are useful for medicines, sanitary aids, or cosmetics.

The present disclosure relates generally to oral compositions and methods for freshening breath and oral cleansing, and more particularly, to oral compositions comprising a combination of an extract of magnolia and a hydrocarbon. The oral compositions are useful for improving oral health, including freshening breath and reducing the adherence of plaque to teeth.

An aqueous solution for intraoral cleaning via irradiation with ultraviolet ray and/or near-ultraviolet visible ray and/or ray in an 800-900 nm near-infrared region is employed as the hydrogen peroxide aqueous solution, wherein a concentration of hydrogen peroxide is 1 w/v % to 7 w/v %, and a concentration of a hydrogen peroxide stabilizer is 81 ppm (mg/L) or less in the aqueous solution.

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. ##STR00001##
wherein the symbols in the formula are defined below:
A: e.g., Benzene, E: e.g., —CH.sub.2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R.sup.1, R.sup.2, R.sup.3: e.g., a halogen atom, R.sup.4: e.g., a C1-C6 alkyl group, R.sup.5: e.g., a hydrogen atom, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d: e.g., a hydrogen atom, R.sup.7: e.g., a hydrogen atom, R.sup.8: e.g., a hydrogen atom, n.sup.1, n.sup.2, n.sup.3: e.g., 1.

The present invention provides hyaluronic acid derivatives including one or more of each of repeating units represented by the formulae (Ia), (Ib), and (Ic) in which certain cationic sites, certain hydrophobic sites, and certain hydrophilic sites have been introduced. In addition, the present invention provides complexes of the hyaluronic acid derivatives with a drug and pharmaceutical compositions including the hyaluronic acid derivatives, in particular, complexes of the hyaluronic acid derivatives with a drug.

Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.

The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.